https://uricatherapeutics.com/wp-content/uploads/2023/04/logo-new2.png
0
0
admin
https://uricatherapeutics.com/wp-content/uploads/2023/04/logo-new2.png
admin2023-06-29 13:17:002023-06-29 13:18:06Urica Therapeutics Announces Topline Data from the Phase 1 Clinical Trial Evaluating Dotinurad in Healthy Volunteers in the United States
https://uricatherapeutics.com/wp-content/uploads/2023/04/logo-new2.png
0
0
Jaclyn Jaffe
https://uricatherapeutics.com/wp-content/uploads/2023/04/logo-new2.png
Jaclyn Jaffe2022-12-14 13:10:452022-12-14 13:17:40Urica Therapeutics Expands Exclusive License Agreement with Fuji Yakuhin Co. Ltd. to Develop Dotinurad in Additional Territories Including Turkey and the Middle East and North Africa
https://uricatherapeutics.com/wp-content/uploads/2023/04/logo-new2.png
0
0
admin
https://uricatherapeutics.com/wp-content/uploads/2023/04/logo-new2.png
admin2022-10-03 17:44:012022-11-14 17:54:30Urica Therapeutics Appoints Seasoned Biotech Executive Jay D. Kranzler, M.D., Ph.D., as Chairman and Chief Executive Officer
https://uricatherapeutics.com/wp-content/uploads/2023/04/logo-new2.png
0
0
admin
https://uricatherapeutics.com/wp-content/uploads/2023/04/logo-new2.png
admin2022-05-31 16:32:212022-12-01 22:12:22Fortress Biotech Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating dotinurad for the Treatment of Gout in the United States
https://uricatherapeutics.com/wp-content/uploads/2023/04/logo-new2.png
0
0
admin
https://uricatherapeutics.com/wp-content/uploads/2023/04/logo-new2.png
admin2021-05-10 17:44:152022-12-01 22:13:44Fortress Biotech Announces Exclusive License Agreement With Fuji Yakuhin to Develop dotinurad in North America and Europe
Scroll to top
